ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.
Beta Drugs Limited has scheduled its 21st Annual General Meeting for September 30, 2026, at its registered office in Baddi, Himachal Pradesh.
Beta Drugs Limited announced the re-appointment of its Statutory Auditor and an Executive Director. These re-appointments are effective from September 2026 and January 2027, respectively.
Beta Drugs Limited announced its board meeting outcome, covering AGM arrangements, auditor appointments, and the re-appointment of its Whole-Time Director, Ashutosh Shukla.
Beta Drugs Limited has scheduled a board meeting for September 3, 2026. The agenda includes fixing the 21st AGM details and approving the Director’s Report.
Beta Drugs Limited approved the allotment of 35,383 bonus equity shares. These shares were issued to holders of Compulsorily Convertible Debentures following their conversion.
Beta Drugs Limited submitted its quarterly Monitoring Agency Report for June 2026. The report tracks the utilization of Rs. 117.01 Crore raised via preferential issues.
Beta Drugs Ltd. reports Q1-FY27 revenue of INR 1,255 Mn with 21.83% EBITDA margin. Diversifying beyond core oncology into IVF via Nivian acquisition.
Beta Drugs submitted revised Limited Review Reports for the quarter ended June 2026, correcting the omission of UDINs as requested by the exchange.
Beta Drugs scheduled a board meeting for July 20, 2026. The board will review unaudited quarterly financial results for the period ended June 2026.